According to a recent report, based on Tβ4 potential anti‐inflammatory molecules and neuroprotective and myelin regeneration molecules and their mechanism of action, Tα1 and Tb4 could be used alone to treat multiple sclerosis (MS) or with other approved applications of drug combination therapy.29 This evidence concerns the gene TAAR1 and myeloid sarcoma.